Skip to main content
2023 Guide to Patient Support Services

Supporting Your Patients with the Resources That Are Most Important to Them

2023 PSS Guide

Enroll Your Patients in a Pharma-Sponsored Support Program to Provide Access to Their Treatment and Resources for Their Journey

Each year, the publishers of Oncology Practice Management update this comprehensive guide to pharma-sponsored patient support programs in the hope it helps you to guide your patients to the tools and resources that provide access to their prescribed medications.

The services provided by each company will vary, but most pharmaceutical companies provide patient education about the disease and the prescribed treatment and offer financial assistance for those patients who meet program requirements. Pharma-sponsored support programs may include services such as:

  • Copay assistance programs for patients with commercial insurance
  • Patient assistance programs for underinsured or uninsured patients
  • Dedicated nurse navigators/case managers
  • Personalized patient support

We think you will agree, these services can be an invaluable help to patients and can alleviate some of the pressure patients experience when dealing with a cancer diagnosis.

In addition to patient support, there are also services to help you and your office staff, such as benefit verification, insurance coverage determination, prior authorizations, and claims/appeals support.

This Guide organizes patient support programs by company name and lists the services each program offers. A list by drug name is included in the index.

We encourage all oncology healthcare providers to use the Guide and share this information with patients. We hope the Guide proves to be a useful tool to you in your practice.

EDITOR’S NOTE: The company profiles in this Guide are based on information posted online by the respective pharmaceutical companies as of December 2022. Every effort has been made to verify the information up to that time. Any updates, including new drugs approved after that time, will not appear in this publication. The Publisher and the Editors are not responsible for any inaccuracies stemming from changes, new drug approvals, or company updates that became available later. Readers are advised to review the websites of each drug company for any updates and revisions.